
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems Inc. has demonstrated strong financial performance, with Q4 revenue reaching $239.7 million, reflecting a year-over-year increase of 24.5%, alongside earnings per share (EPS) of $1.15, outperforming consensus estimates. The consistent growth in utilization of the Inspire therapy, rising from 1.1 procedures per month in 2021 to an expected 1.8 in 2024, indicates increasing acceptance and demand for its neurostimulation technology. Additionally, the anticipated expansion in therapy penetration driven by new implanting centers, improved diagnosis rates, and upcoming innovations suggests significant growth potential for the company in both the U.S. and international markets.
Bears say
Inspire Medical Systems Inc faces a negative outlook due to several entrenched challenges, including slower penetration of implant centers, reduced utilization rates, and a protracted path to profitability. The firm is experiencing stagnation in its volume growth, heightened competition from new market entrants, and concerns over decreased physician reimbursement undermining the adoption of its procedure by new ENT specialists. Additionally, Inspire Medical's reliance on its sales force to drive treatment adoption, along with potential supply chain risks, may further impede its business growth prospects.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares